about
Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated ReviewHigh-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry.High-dose chemotherapy with mitoxantrone + melphalan and autologous stem cell rescue in metastatic breast cancer patients: a study of feasibility and tolerability.Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim.Thrombotic thrombocytopenic purpura: a rare late complication of allogeneic bone marrow transplantation.Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry.The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation.A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease.Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective studyThe favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.Internal iliac artery perforation following bone marrow aspiration in a patient with no previously identified risk factors: a case report and review of the literature.Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients.Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents.An old drug with a new future: bendamustine in multiple myeloma.Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization.High-dose chemotherapy for germ cell tumors: do we have a model?Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation.Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.The role of tandem stem cell transplantation for multiple myeloma patients.Sorafenib for the treatment of multiple myeloma.Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study.Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow TransplantaShort and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience.Systemic aspergillosis in a patient with non-Hodgkin's lymphoma developing acute graft-versus-host disease after autologous peripheral blood stem cell transplantation.High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer.Mobilization of hematopoietic stem cells with lenograstim in healthy donors: efficacy and safety analysis according to donor age.Basal CD34+ Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of Granulocyte Colony-Stimulating Factor: A Longitudinal, Prospective, Observational, Single-Center, Cohort Study.Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.Differences in transplant-related complications between hematologic malignancies and solid tumors receiving high-dose chemotherapy and autologous peripheral blood stem cell transplantation.Utility of the clinical practice of administering thrombophilic screening and antithrombotic prophylaxis with low-molecular-weight heparin to healthy donors treated with G-CSF for mobilization of peripheral blood stem cells.A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model.Venetoclax for the treatment of chronic lymphocytic leukemia.Autologous stem cell transplantation in multiple myeloma is not dead but alive and well.
P50
Q26770716-60347386-94CF-4304-A54F-B4B1C62C47ADQ31034714-E1C2EFE0-635E-4BE1-B7BA-BE5A957165ABQ33359253-29EC5B25-7B39-4AD8-A880-F9639148A0FFQ33366294-D0359027-2F40-432C-A1D0-AFA9635422D4Q33490059-534F6D0B-9842-402B-850D-7BF4B538B4CEQ34366379-9D791EDD-97B0-4686-B6D3-C5F349F7C8ADQ35874039-F8C475C7-FFFF-467C-9357-C204AE0BC652Q36425924-A66EAD85-CBBB-4356-AE95-4DA8C20A8F72Q36569033-6F72BB46-21AB-4848-AB30-1138DAA6021FQ36613992-917D3AA0-A554-4B4D-ABE7-B0F7304805BAQ36691438-7CCB9FDB-54AB-41B1-8371-CE48AF2B4B42Q37945432-EB3EF9B8-4ED4-45DD-B18F-467812C34BCEQ38040419-0C41A7B8-E458-4E18-94A6-9BA42A2F744FQ38109898-A5785144-44FE-4C94-8B68-78798A14B393Q38139989-48A96A38-4E95-472C-91F0-F0DCC579A7D9Q38193590-9AF789B8-6526-4E61-97D1-296EEA620F3BQ38253101-D0848EC2-94BB-40DA-AAEC-3A49BA196608Q38260255-C76DFB19-B62A-4778-91BF-956A681F9F9AQ38417073-7F5B863B-86F4-443F-A4D2-9E1CB0F66AF1Q38451287-BB946A42-F354-4125-809E-26684E3A4D2AQ38573871-B33A510C-00EE-4F0B-BBA7-E05A3D70B265Q38664909-1ED983F8-BD0B-4FD9-83B7-B33FBA5DF298Q38677358-DF10752C-9740-4975-813A-CE50E62117CCQ38783055-54BAC1EF-D90C-4BBD-BD18-3236B5D38A4BQ38797546-17D32BC6-85A6-450D-8192-0AD64DA707AEQ40150538-CE5920FB-78A5-4AF0-89D1-45E4B5406D56Q40211698-9389EA53-3AA7-4135-A881-DBB46FAACEE3Q40237545-3B9A7F21-A24C-4960-AA40-17ED89EC0BA1Q40398250-2C0D879B-7A94-4605-9C64-C888E294DF2FQ40579674-740A953A-A6EB-4E75-A946-6A5E076C4E76Q40847140-7FBD0347-B414-4135-AA72-844BABCE8701Q41505002-EEAB2684-8067-473C-9C68-57E34814C90AQ42507670-E5F90A0D-D065-4AD7-BB88-EA75CEA7315FQ43714381-D38527BE-59E7-4270-A8FD-0AE4CF0DCEE5Q44301366-9018895C-6CFF-409C-9308-BC73FA444B93Q44647872-D96BD893-3945-4516-88D6-D636C3AA9F1CQ47284603-87C176A2-CBDE-4235-AA3F-AEE8C798E32FQ47654723-10AD8564-40A2-470C-8EE6-14F773A68957Q47875923-10BFE2A0-6724-4FB4-8218-1FD7F18E09ACQ48058540-232A0931-FEC2-4BEE-B0B8-F5A87CE505F4
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Massimo Martino
@ast
Massimo Martino
@en
Massimo Martino
@es
Massimo Martino
@nl
Massimo Martino
@sl
type
label
Massimo Martino
@ast
Massimo Martino
@en
Massimo Martino
@es
Massimo Martino
@nl
Massimo Martino
@sl
prefLabel
Massimo Martino
@ast
Massimo Martino
@en
Massimo Martino
@es
Massimo Martino
@nl
Massimo Martino
@sl
P1053
K-7479-2013
P106
P1153
55402092300
P21
P31
P3829
P496
0000-0002-3987-419X
P569
2000-01-01T00:00:00Z